The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

Trapped-ion quantum computing leader IonQ (NYSE: IONQ) is emerging as a potential leader in the commercialization of quantum ...

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...